HCW Biologics Q1 Delivers $6.5M Revenue, $3.5M Profit and $7M License Deal
HCW Biologics reported Q1 revenue of $6.5 million and net income of $3.5 million, driven by a $3.5M cash and $3.5M equity upfront fee from a Trimmune license. The company expects Phase 1 readout for HCW9302 alopecia areata trials from two active sites in H1 2026 with no dose‐limiting toxicities.
1. Clinical Trial Progress
HCW Biologics is on track to report preliminary data from the first two dose levels of its Phase 1 HCW9302 trial in alopecia areata in H1 2026. Two clinical sites are actively enrolling, enrollment remains on schedule, and no dose‐limiting toxicities have been observed in treated patients.
2. Trimmune Licensing Agreement
On March 16, 2026, the company closed an exclusive worldwide license for HCW11-006 with Trimmune, receiving $3.5 million in gross cash proceeds (net $2.9M) and a $3.5 million transferable equity stake. HCW Biologics recognized $6.5 million in revenue for Q1, including $470,000 in deferred revenue tied to this deal.
3. Q1 Financial Performance
For the quarter ended March 31, 2026, revenues rose to $6.5 million from $5.1 million a year earlier, driven by licensing arrangements. R&D expenses fell 15% to $1.3 million, G&A expenses declined 18% to $1.8 million, and the company swung from a $2.2 million loss to a $3.5 million profit.
4. Future Outlook and Funding
HCW Biologics completed a $1.5 million equity financing in February via pre-funded and common stock warrants, while also restructuring existing warrants. Despite recent cash inflows, the company notes substantial doubt about its ability to continue as a going concern for the next 12 months without additional financing.